Fidia will take over a line of drugs from Sanofi. A deal estimated at 200 million

Fidia one step away from Sanofi gynecological products. Deal on the Italy-France axis

Italy And France they do business in the pharmaceutical industry. Phidias is close to purchasing a line of medicines owned by Sanofi. The main French company sells gynecological products for around 200 million. The agreement exists but the signatures are still missing, the agreement – reports Il Sole 24 Ore – will be completed and signed on first of July, so the figure is still confidential. Before giving the final approval, the French government is evaluating all aspects of the operation, considering that national pharmaceutical companies are considered fundamental assets on which to exercise “golden power” (the possibility of authorizing or blocking agreements with foreign countries).

The contract – continues Il Sole – is in any case nearing completion, and an indicative value has been unofficially leaked out, around 200 million, which Phidias will have to pay to Sanofi. For Fidia, the perspective that this acquisition creates is important: one estimated growth of 5-6% per year and a significant expansion in central and sub-Saharan Africa, in the Middle East up to some Asian countries, more precisely in Hong Kong, Indonesia, the Philippines and finally arriving in Australia. The operation with Sanofi is the third in early 2024, after the acquisition of the ophthalmic business of Sanifarma and after the recent commercial agreement with the multinational Novartis for the distribution of six ophthalmological medicinal specialties for the treatment of glaucoma.